AltaRex Plans U.S. Filing Despite Mixed Results Of OvaRex Trials
By Kim Coghill
Monday, January 28, 2002
Despite inconsistent results in Phase IIb trials, Canadian company AltaRex Corp. intends this year to file a rolling biologics license application for its late-stage ovarian cancer drug, OvaRex.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.